Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Key Highlights
- ➤Vogenx (VOGX) initiated Phase 2b EMERGE study for PBH in October 2026
- ➤EMERGE topline results expected in the second half of 2027
- ➤Vogenx completed $93.4 million IPO, receiving approximately $84.4 million net
- ➤Cash, equivalents and marketable securities totaled $82.1 million at September 30
- ➤Third-quarter net loss widened to $4.9 million, or $0.47 per share
Expert Statements
James Green, Chief Executive Officer of Vogenx
“Our third quarter performance marks a pivotal milestone for Vogenx following our successful public listing in August”
James Green, Chief Executive Officer of Vogenx
“The EMERGE study is now up and running and we have added critical headcount across the Company, positioning us to advance the development of mizagliflozin for both post-bariatric hypoglycemia (PBH) and gastroparesis.”
RALEIGH, NC / ACCESS Newswire / November 6, 2026 / Vogenx, Inc. (NASDAQ:VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced its financial results for the third quarter and provided a corporate update.
"Our third quarter performance marks a pivotal milestone for Vogenx following our successful public listing in August," said James Green, Chief Executive Officer of Vogenx. "The EMERGE study is now up and running and we have added critical headcount across the Company, positioning us to advance the development of mizagliflozin for both post-bariatric hypoglycemia (PBH) and gastroparesis."
Get started
Create a free account to read the full story.